Pharmaceutical composition for preventing or treating drug addiction containing endocannabinoid

A pharmaceutical composition using endocannabinoids addresses the limitations of current drug addiction treatments by reducing cocaine self-administration in primates, providing a promising new approach to managing drug addiction through the endocannabinoid system.

WO2024237448A1PCT designated stage expired Publication Date: 2024-11-21CHUNGBUK NAT UNIV IND ACADEMIC COOP FOUNDATION +3
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/003290
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-03-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for drug addiction are limited, and there is a need for new drugs to effectively address cocaine addiction, which involves complex interactions with the endocannabinoid system, where the effects of cannabinoids on cocaine-induced self-administration are unclear.

Method used

A pharmaceutical composition containing endocannabinoids, such as arachidonoylethanolamine and 2-Arachidonyl glyceryl ether, is developed to inhibit drug self-administration responses in individuals with drug addiction, administered via various routes including injection, granules, or oral forms, incorporating common pharmaceutical excipients and carriers.

Benefits of technology

The endocannabinoid-based composition effectively reduces cocaine self-administration in primates, demonstrating a dose-dependent suppression of drug dependence, offering a novel approach to treating drug addiction and improving public health outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024003290_21112024_PF_FP_ABST
    Figure KR2024003290_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating drug addiction. According to one aspect, the endocannabinoid is effective in treating drug addiction by reducing the desire for drug self-administration, and has the useful effect of contributing to the improvement of national health.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition containing endocannabinoids for preventing or treating drug addiction

[0001] It relates to a pharmaceutical composition for preventing or treating drug addiction.

[0002] Cannabinoids are psychoactive drugs extracted from the cannabis plant. The main ingredient, Δ9-tetrahydrocannabinol (THC), acts on the CB1 receptor, influencing neurotransmission at nerve cell synapses. Substances similar to THC also exist in humans and animals and function as neurotransmitters; these are called endocannabinoids.

[0003] Endocannabinoids function as neurotransmitters at nerve cell synapses. Synapses are the structural sites where information is transmitted between neurons. Typically, neurotransmitters are released from the presynapse into a space a few nanometers away called the synaptic cleft. Neurotransmitters in the synaptic cleft bind to neurotransmitter receptors located on the postsynaptic surface, facing the presynapse. Uniquely, endocannabinoids are retrograde messengers, unlike typical neurotransmitters, which are released from the postsynapse and act on the presynapse. Specifically, when calcium ion concentration rises within the postsynapse, endocannabinoid synthesis is stimulated from membrane lipids, leading to their release. These endocannabinoids bind to CB1 receptors located on the presynaptic surface, inducing changes in presynaptic function. CB1 receptors are a type of G protein-coupled receptor that inhibit the function of presynaptic calcium channels through intracellular signaling. Presynaptic calcium channel function plays an essential role in the release of neurotransmitters. Therefore, CB1 receptors inhibit the release of neurotransmitters such as GABA and glutamate from the presynapse.

[0004] Cocaine, an addictive drug, is an alkaloid extracted from the coca leaf, a plant native to the coca plant. It is currently one of the world's most problematic narcotics. Absorbed through the human mucosa, cocaine acts on sensory nerve endings, numbing sensations like pain and taste. Therefore, its use as a local anesthetic during surgery and examinations began in 1862.

[0005] However, if you absorb a large amount or use it repeatedly, it can cause addiction, which can lead to mental illnesses such as depression, anxiety, sleep disorders, chronic fatigue, and mental confusion, as well as nutritional disorders. Cocaine addiction is a type of drug addiction that occurs through injection, ingestion, or nasal inhalation of cocaine. The intoxicating dose is 0.1 g, and the lethal dose is 1.0 g. In acute poisoning due to large-scale use, it starts with dizziness, pale face, and pupillary scattering, and then you fall into a state of confusion, and you can see mental confusion, hallucinations, auditory hallucinations, and fainting, and it can cause respiratory distress or collapse, leading to death.

[0006] Habitual addiction due to prolonged use resembles morphine addiction, but it also causes significant physical exhaustion, such as weakness and wasting, and mental problems such as difficulty concentrating and moral deterioration. In addition, cocaine can cause hallucinations, such as somatosensory hallucinations, where the user feels as if bugs or small animals are crawling on the body. Furthermore, cocaine can induce convulsions at high doses (Kramer LD, et al., Am J Drug Alcohol Abuse, 16: 307-317 [Medline]).

[0007] Cocaine acts as a central nervous system stimulant, and self-administration in primates is characterized by increased drug use when administered freely using a self-administration device. Cocaine-induced changes in endocannabinoid nervous system activity are associated with cocaine dependence, but the role of cannabinoids in cocaine-induced self-administration remains unclear.

[0008] In addition, the current drugs used to treat drug addiction are extremely limited, and the development of new drug addiction treatment drugs is necessary to address this unmet medical need.

[0009] One aspect is to provide a pharmaceutical composition for preventing or treating drug addiction containing endocannabinoids as an active ingredient.

[0010] Another aspect is to provide a health functional food for preventing or improving drug addiction containing endocannabinoids as an active ingredient.

[0011] Another aspect is the provision of a method for preventing or treating drug addiction comprising administering to a subject in need thereof an effective amount of endocannabinoids.

[0012] Another aspect provides the use of endocannabinoids for the manufacture of pharmaceutical compositions for the prevention or treatment of drug addiction.

[0013]

[0014] One aspect provides a pharmaceutical composition for preventing or treating drug addiction containing endocannabinoids as an active ingredient.

[0015] The term "cannabinoid" or "cannabinoid" as used herein may refer to a class of various compounds that activate cannabinoid receptors, and the cannabinoids may include phytocannabinoids, endocannabinoids, and synthetic cannabinoids.

[0016] The term "cannabinoid receptor" as used herein refers to a receptor activated by cannabinoids, and may include cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), cannabinoid receptor type 3 (CB3), G protein-coupled receptor (GPR55), GRP119 and GPR18, peroxisome proliferator-activated receptor (PPAR), and transient receptor potential vanilloid 1 (TRPV1).

[0017] The term "phytocannabinoids" as used herein may refer to cannabinoids found in cannabis and various plant species, and may include tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and multicyclic phenolic compounds structurally related to THC.

[0018] The term "endocannabinoids" or "endogenous cannabinoids" as used herein may refer to fatty acid derivatives produced within the body that activate cannabinoid receptors.

[0019] The term "synthetic cannabinoids" as used herein may mean substances artificially synthesized based on the structure of plant cannabinoids or endocannabinoids.

[0020] In one specific example, the endocannabinoid may be at least one selected from the group consisting of Arachidonoylethanolamine, 2-Arachidonoylglycerol, 2-Arachidonyl glyceryl ether, N-Arachidonoyl dopamine, Virodhamine, and Lysophosphatidylinositol.

[0021] The term "active ingredient" in this specification may mean an ingredient that exhibits the desired activity alone or can exhibit the activity together with a carrier that is inactive in itself.

[0022] In one specific example, the drug may be one or more selected from the group consisting of narcotics, psychotropic drugs, and cannabis.

[0023] The term "narcotic" as used herein may mean poppy, opium, coca leaf and its alkaloids and chemical synthetic products, and may include cocaine, codeine, morphine, heroin, methadone, fentanyl, krokodil, hydromorphinol or combinations thereof.

[0024] The term "psychotropic drug" in this specification may refer to a substance that acts on the human central nervous system and may cause serious harm when abused, and may include LSD, gomeo, kratom, amphetamine (Adderall), methamphetamine, MDMA, yaba, ketamine, benzodiazepine, zolpidem, propofol, eszopiclone, methylphenidate, GHB, cathinone (bath salts), barbiturates, phentermine, or a combination thereof.

[0025] The term "cannabis sativa L." as used herein may collectively refer to cannabis chemovars and their variants, including varieties var. indica and var. kafiristanica, Cannabis sativa subspecies sativa, Cannabis sativa subspecies indica, Cannabis sativa subspecies ruderalis, and genetically hybridized, selfed, or hybridized plants thereof, which contain various types of cannabinoid compounds known as pharmaceutical ingredients. In addition, it may refer to cannabis {Cannabis sativa L.} and its resin (resin), and all products manufactured using cannabis or its resin as a raw material.

[0026] As used herein, the term "addiction" may encompass physical or psychological dependence on a substance, unless otherwise specified. Addiction may involve withdrawal symptoms or mental or physical distress when the substance is withdrawn. In some embodiments, addiction may include one or more of the following: drug preference in the subject, drug dependence, habit formation, neurological and / or synaptic changes, development of brain reward system dysfunction, behavioral changes, or other signs or symptoms of addiction.

[0027] The terms "drug addiction" and "psychotropic drug addiction" used herein can refer to a state in which a person is unable to lead a normal life without the long-term use of narcotics or psychotropic drugs. While the symptoms of drug addiction vary slightly depending on the type of drug, the World Health Organization (WHO) defines common characteristics as follows: First, there is a strong desire to continue using the drug and to obtain it by any means necessary. Second, there is a tendency to continuously increase the dosage. Third, there is a tendency to become mentally and physically dependent on the drug. Fourth, it is detrimental not only to the individual but also to society.

[0028] In one specific example, the drug may be at least one selected from the group consisting of opium, cocaine, codeine, morphine, heroin, methadone, fentanyl, krokodil, hydromorphinol, LSD, gomeo, kratom, amphetamine (Adderall), methamphetamine, MDMA, yaba, ketamine, benzodiazepine, zolpidem, propofol, eszopiclone, methylphenidate, GHB, cathinone (bath salts), barbiturates, phentermine, cannabis, nicotine, and alcohol.

[0029] In one specific example, the endocannabinoid may suppress a drug self-administration response in a drug-addicted individual.

[0030] In one specific example, the pharmaceutical composition for preventing or treating drug addiction containing the endocannabinoid as an active ingredient may be prepared in any one of the following forms: injection, granule, powder, tablet, pill, capsule, suppository, gel, suspension, emulsion, drop or liquid, according to a conventional method.

[0031] In one specific example, the pharmaceutical composition for preventing or treating drug addiction containing the endocannabinoid as an active ingredient may further include one or more additives selected from the group consisting of suitable carriers, excipients, disintegrants, sweeteners, coating agents, bulking agents, lubricants, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, dispersants, surfactants, binders, and lubricants commonly used in the manufacture of pharmaceutical compositions.

[0032] Specifically, carriers, excipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. These solid preparations may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, and the like, into the composition. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients such as wetting agents, sweeteners, flavoring agents, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents can be propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Base materials for suppositories include witepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.

[0033] In one embodiment, the pharmaceutical composition may be administered to a subject in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, intranasal, inhalational, topical, rectal, oral, intraocular, or intradermal routes.

[0034] The preferred dosage of the endocannabinoid may vary depending on the subject's condition and weight, the type and severity of the disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art. In one embodiment, but not limited to, the endocannabinoid may be administered at a dosage ranging from 0.01 to 10 mg / kg, 0.01 to 2 mg / kg, or 0.1 to 1 mg / kg. Administration may be administered once a day or divided into several doses, but is not limited thereto.

[0035] The above 'subject' may be a mammal including a human, but is not limited to these examples.

[0036] The term “prevention” in this specification may comprehensively mean preventing drug addiction in advance or reducing the possibility or frequency of occurrence by administering the composition.

[0037] The term “treatment” in this specification may mean any act in which symptoms of drug addiction and psychotropic drug addiction are improved or beneficially changed by administration of the composition.

[0038] Another aspect provides a health functional food for preventing or improving drug addiction containing endocannabinoids as an active ingredient.

[0039] The above endocannabinoids, active ingredients, drugs, addiction and prevention are as described above.

[0040] The term "improvement" in this specification may mean any action that at least reduces the severity of symptoms, for example, parameters related to the alleviation or treatment of conditions related to drug addiction and psychotropic drug addiction, by administration of the composition.

[0041] The term "functional food" in this specification is synonymous with "food for special health use" (FoSHU), and may refer to foods with high medical or therapeutic effects that are processed to efficiently exhibit bioregulatory functions in addition to providing nutrition. "Functionality" here may refer to regulating nutrients for the structure and function of the human body or achieving beneficial effects for health purposes, such as physiological effects.

[0042] The above health functional food can be manufactured using methods commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art. To formulate the health functional food, food-wise acceptable carriers or additives can be used, and any carrier or additive known to be usable in the art can be used to manufacture the desired formulation.

[0043] In addition, the food composition may include additional ingredients commonly used in food compositions to improve odor, taste, sight, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr), etc.; and amino acids such as lysine, tryptophan, cysteine, and valine.

[0044] In addition, the food composition may include food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), sterilizers (bleaching powder and high-purity bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar colorants, etc.), colorants (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, D-potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (glucose fillers), film-forming agents, gum-forming agents, foam suppressants, solvents, and improvers. The above additives can be selected according to the type of food and used in an appropriate amount.

[0045] The above health functional food can be formulated into a conventional health functional food formulation known in the art. Specifically, it can be manufactured into a general formulation such as a powder, granule, tablet, pill, capsule, suspension, emulsion, syrup, infusion, liquid, extract, etc., and can be manufactured into any health food form such as dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, jelly, ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.

[0046] Another aspect provides a method of preventing or treating drug addiction comprising administering to a subject in need thereof an effective amount of endocannabinoids.

[0047] The above endocannabinoids, drugs, addiction, prevention and treatment are as described above.

[0048] In one embodiment, the effective amount of the endocannabinoid can be administered to the subject in a conventional manner via intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, intranasal, inhalation, topical, rectal, oral, intraocular, or intradermal routes.

[0049] The preferred dosage of the endocannabinoid may vary depending on the subject's condition and weight, the type and severity of the disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art. In one embodiment, but not limited to, the endocannabinoid may be administered at a dosage ranging from 0.01 to 10 mg / kg, 0.01 to 2 mg / kg, or 0.1 to 1 mg / kg. Administration may be administered once a day or divided into several doses, but is not limited thereto.

[0050] Another aspect provides the use of endocannabinoids for the manufacture of pharmaceutical compositions for the prevention or treatment of drug addiction.

[0051] The above drugs, addictions, prevention, treatment and endocannabinoids are as described above.

[0052] A pharmaceutical composition for preventing or treating drug addiction containing endocannabinoids as an active ingredient according to the daily aspect is a novel drug addiction treatment agent, which is effective in treating drug addiction by reducing the desire for drug self-administration, and has a useful effect that can contribute to improving public health.

[0053] Figure 1 is a graph showing that self-administration response is induced in primates.

[0054] Figure 2 is a graph showing that the self-administration response is suppressed by 2-AG treatment.

[0055] Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are provided solely to illustrate the present invention, and the scope of the present invention is not limited by the following examples.

[0056]

[0057] Experimental Example 1. Primate Drug Addiction Model

[0058] To determine the therapeutic effect of endocannabinoids on drug addiction, a drug addiction model was utilized in which cocaine was dispensed from a spout upon pressing a lever using a primate self-administration device.

[0059] Specifically, marmoset monkeys [Callithrix jacchus; 247-320 g, 3-4 year-old adult males and 1 female] were given dextrose as a training food and reward in a self-administration experimental apparatus modified from the operant chamber of Med Associates. They were trained using dextrose for 3 hours a day, 5 days a week for a total of 10-11 weeks, and then conducted a drug addiction assessment test using 0.4 mg / mL of cocaine instead of dextrose for 5-9 weeks. During the drug addiction test, the test was conducted in an experimental apparatus equipped with two levers, an active lever and an inactive lever, and 0.1 mL of cocaine was delivered to the marmosets through the snout for each active lever response. Conversely, dextrose was delivered for each inactive lever response. If active lever responses were induced more than 20 times for 3 consecutive days, and if the statistical difference between active and inactive lever responses persisted, or if the ratio of active and inactive lever responses was 0.8:0.2 to 1.0:0.0, dependence on cocaine was determined to have been formed.

[0060] The experimental results are shown in Fig. 1. The active lever responses and inactive lever responses during the marmoset cocaine self-administration test are shown. The x-axis session represents the test performance day of the cocaine self-administration test, and the y-axis represents the number of responses on the active and inactive levers. The number of active lever responses exceeded 20 in all sessions except Session 15, and statistical differences between the active and inactive lever responses were observed in Session 7, Sessions 19 to 23, and Session 25, so it was determined that the marmoset had developed dependence on cocaine.

[0061] Therefore, it was confirmed that cocaine self-administration was induced in primates through the above method.

[0062]

[0063] Experimental Example 2. Confirmation of changes in self-administration response due to endocannabinoid treatment.

[0064] Using the above primate drug addiction model, changes in self-administration response due to endocannabinoid treatment were confirmed.

[0065] Specifically, as described above in Experimental Example 1, when a change from the baseline of active lever responses was observed to be within 20% for 3 consecutive days in marmosets that had developed cocaine dependence, vehicle or 2-AG (0.01, 0.1, 0.01 mg / kg) was administered intraperitoneally 1 hour before cocaine self-administration. If the number of active lever responses decreased to less than 20 due to 2-AG administration, dependence was evaluated to have been suppressed.

[0066] The experimental results are shown in Fig. 2. The active and inactive lever responses are shown when testing the effects of vehicle and 2-AG pretreatment on cocaine self-administration in marmosets. The x-axis session represents the test day of the cocaine self-administration test, and the y-axis represents the number of responses on the active and inactive levers. Vehicle, 2-AG 0.01 mg / kg, 2-AG 0.1 mg / kg, and 2-AG 1 mg / kg were administered in sessions 4, 8, 12, and 16, respectively. Vehicle and 2-AG 0.01 mg / kg did not reduce dependence, but 2-AG 0.1 and 1 mg / kg reduced cocaine dependence in marmosets.

[0067] Therefore, it was confirmed that drug self-administration response was dose-dependently reduced by treatment with 2-arachidonoylglycerol (2-AG), an endocannabinoid.

Claims

1. A pharmaceutical composition for preventing or treating drug addiction containing endocannabinoids as an active ingredient.

2. A pharmaceutical composition for preventing or treating drug addiction according to claim 1, wherein the endocannabinoid is at least one selected from the group consisting of Arachidonoylethanolamine, 2-Arachidonoylglycerol, 2-Arachidonyl glyceryl ether, N-Arachidonoyl dopamine, Virodhamine, and Lysophosphatidylinositol.

3. A pharmaceutical composition for preventing or treating drug addiction according to claim 1, wherein the drug is at least one selected from the group consisting of narcotics, psychotropic drugs, and cannabis.

4. A pharmaceutical composition for preventing or treating drug addiction according to claim 1, wherein the drug is at least one selected from the group consisting of opium, cocaine, codeine, morphine, heroin, methadone, fentanyl, crocodile, hydromorphinol, LSD, gomeo, kratom, amphetamine (Adderall), methamphetamine, MDMA, yaba, ketamine, benzodiazepine, zolpidem, propofol, eszopiclone, methylphenidate, GHB, cathinone (bath salt), barbiturate, phentermine, cannabis, nicotine, and alcohol.

5. A pharmaceutical composition for preventing or treating drug addiction, wherein the endocannabinoid in claim 1 suppresses the drug self-administration response of a drug-addicted individual.

6. Health functional food containing endocannabinoids as an active ingredient for preventing or improving drug addiction.

7. A health functional food for preventing or improving drug addiction, wherein the endocannabinoid in claim 6 is at least one selected from the group consisting of Arachidonoylethanolamine, 2-Arachidonoylglycerol, 2-Arachidonyl glyceryl ether, N-Arachidonoyl dopamine, Virodhamine, and Lysophosphatidylinositol.

8. A health functional food for preventing or improving drug addiction according to claim 6, wherein the drug is at least one selected from the group consisting of opium, cocaine, codeine, morphine, heroin, methadone, fentanyl, crocodile, hydromorphinol, LSD, gomeo, kratom, amphetamine (Adderall), methamphetamine, MDMA, yaba, ketamine, benzodiazepine, zolpidem, propofol, eszopiclone, methylphenidate, GHB, cathinone (bath salt), barbiturate, phentermine, cannabis, nicotine, and alcohol.

9. A method for preventing or treating drug addiction, comprising administering an effective amount of endocannabinoids to a subject in need thereof.

10. Use of endocannabinoids for the preparation of a pharmaceutical composition for the prevention or treatment of drug addiction.

Citation Information

Patent Citations

  • Use of the aminoalkylindole JWH-073-m4 and related compounds as neutral CB1 recptor antagonists for the treatment of alcoholism, drug abuse, obesity, and obesity-related diseases

    US20150266820A1

  • Modified Release Multi-Layer Tablet Cannabinoid Formulations

    US20180263913A1

  • Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use

    US20220040125A1

  • Formulations and methods for treating acute cannabinoid overdose

    US20220151990A1

  • Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids

    US20220265675A1